Qifeng Song

Title: Qifeng Song: Innovator in Antibody Drug Development

Introduction

Qifeng Song is a prominent inventor based in Jiangsu, China. He has made significant contributions to the field of antibody drugs, particularly through his innovative research and development efforts. His work focuses on creating effective therapeutic solutions for cancer treatment.

Latest Patents

Qifeng Song holds a patent for an anti-CD47 antibody and its applications. This patent, which is crucial in the technical field of antibody drugs, describes an anti-CD47 antibody or an antigen-binding fragment thereof. The pharmaceutical composition derived from this antibody exhibits significant antitumor activity and high affinity with the human CD47 protein. It effectively eliminates the capability of SIRPa to bind to CD47 on the surface of cells, while also demonstrating minimal hemoagglutination activity. This makes it a promising candidate for the preparation of anti-tumor drugs. He has 1 patent to his name.

Career Highlights

Qifeng Song is associated with Nanjing Sanhome Pharmaceutical Co., Ltd., where he continues to advance his research in antibody drug development. His work has positioned him as a key figure in the pharmaceutical industry, particularly in the area of cancer therapeutics.

Collaborations

He collaborates with notable colleagues, including Yong Wang and Liwen Zhao, who contribute to his research endeavors and help drive innovation in the field.

Conclusion

Qifeng Song's contributions to the development of antibody drugs, particularly his work on the anti-CD47 antibody, highlight his role as an influential inventor in the pharmaceutical industry. His ongoing research promises to enhance cancer treatment options and improve patient outcomes.